接受嵌合抗原受体相关毒性治疗的危重患者:一项多中心研究
这项回顾性多中心队列研究纳入美国9个中心2017年11月至2019年5月期间接受嵌合抗原受体T细胞治疗(阿基仑赛)后因细胞因子释放综合征或免疫效应细胞相关神经毒性综合征入ICU的105例成人患者。入ICU时66.7%为3-4级毒性;ICU期间79%出现≥3级毒性,但需要血管升压药(18.1%)、机械通气(10.5%)和透析(2.9%)不常见。ICU死亡率为8.6%,仅3例死亡与细胞因子释放综合征或免疫效应细胞相关神经毒性综合征相关。中位总生存期为10.4个月(95%CI,6.64-未达)。
要点
- 接受阿基仑赛治疗后因细胞因子释放综合征或免疫效应细胞相关神经毒性综合征入ICU的105例成人中,入ICU时66.7%为3-4级毒性。
- ICU期间79%出现≥3级毒性,但需血管升压药18.1%、机械通气10.5%、透析2.9%,器官支持需求不常见。
- ICU死亡率为8.6%,仅3例死亡与细胞因子释放综合征或免疫效应细胞相关神经毒性综合征相关。
- 中位总生存期10.4个月(95%CI,6.64-未达),毒性分级或器官支持对总生存期无影响,较高累积皮质类固醇剂量与总生存期和无进展生存期降低相关。
适用人群与场景
- 美国9个中心2017年11月至2019年5月期间接受嵌合抗原受体T细胞治疗(阿基仑赛)后因细胞因子释放综合征或免疫效应细胞相关神经毒性综合征入ICU的成人患者。
研究设计与关键结果
- 研究类型为回顾性队列研究,纳入105例接受阿基仑赛并因细胞因子释放综合征或免疫效应细胞相关神经毒性综合征入ICU的成人患者。
- 入ICU时66.7%为3-4级毒性;15.2%为3-4级细胞因子释放综合征,64%为3-4级免疫效应细胞相关神经毒性综合征。
- ICU期间细胞因子释放综合征发生率77.1%,免疫效应细胞相关神经毒性综合征84.8%,61.9%同时发生两种毒性。
- ICU期间79%出现≥3级毒性;需血管升压药18.1%、机械通气10.5%、透析2.9%。
- 免疫效应细胞相关脑病评分<3占69.7%,癫痫发作20.2%,癫痫持续状态5.7%,运动缺陷12.4%,脑水肿7.9%。
- ICU死亡率为8.6%,仅3例死亡与细胞因子释放综合征或免疫效应细胞相关神经毒性综合征相关。
- 中位总生存期10.4个月(95%CI,6.64-未达);毒性分级或器官支持对总生存期无影响;较高累积皮质类固醇剂量与总生存期和无进展生存期降低相关。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于接受嵌合抗原受体T细胞治疗(阿基仑赛)后因细胞因子释放综合征或免疫效应细胞相关神经毒性综合征入ICU的成人患者,尽管3-4级毒性常见,但需血管升压药、机械通气和透析的比例较低,ICU死亡率8.6%。
- 免疫效应细胞相关脑病评分<3、癫痫发作、癫痫持续状态、运动缺陷和脑水肿较常见。
- 较高累积皮质类固醇剂量与总生存期和无进展生存期降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
DESIGN: Retrospective cohort study.
SETTING: Nine centers across the U.S. part of the chimeric antigen receptor-ICU initiative.
PATIENTS: Adult patients treated with chimeric antigen receptor T-cell therapy who required ICU admission between November 2017 and May 2019.
INTERVENTIONS: Demographics, toxicities, specific interventions, and outcomes were collected.
RESULTS: One-hundred five patients treated with axicabtagene ciloleucel required ICU admission for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome during the study period. At the time of ICU admission, the majority of patients had grade 3-4 toxicities (66.7%); 15.2% had grade 3-4 cytokine release syndrome and 64% grade 3-4 immune effector cell-associated neurotoxicity syndrome. During ICU stay, cytokine release syndrome was observed in 77.1% patients and immune effector cell-associated neurotoxicity syndrome in 84.8% of patients; 61.9% patients experienced both toxicities. Seventy-nine percent of patients developed greater than or equal to grade 3 toxicities during ICU stay, however, need for vasopressors (18.1%), mechanical ventilation (10.5%), and dialysis (2.9%) was uncommon. Immune Effector Cell-Associated Encephalopathy score less than 3 (69.7%), seizures (20.2%), status epilepticus (5.7%), motor deficits (12.4%), and cerebral edema (7.9%) were more prevalent. ICU mortality was 8.6%, with only three deaths related to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Median overall survival time was 10.4 months (95% CI, 6.64-not available mo). Toxicity grade or organ support had no impact on overall survival; higher cumulative corticosteroid doses were associated to decreased overall and progression-free survival.
CONCLUSIONS: This is the first study to describe a multicenter cohort of patients requiring ICU admission with cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Despite severe toxicities, organ support and in-hospital mortality were low in this patient population.
参考来源
- Gutierrez C, Brown ART, May HP, et al. Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study. Crit Care Med. 2022. PMID: 34259446. doi:10.1097/CCM.0000000000005149
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。